Serina Therapeutics (SER) Return on Capital Employed (2019 - 2026)
Serina Therapeutics (SER) posted Return on Capital Employed of 392.58% for Q4 2025, up 68.28% sequentially from 1237.5% in Q3 2025, and down 3090.0% YoY from 13.13% in Q4 2024.
Serina Therapeutics (SER) Return on Capital Employed (2019 - 2026) Analysis & Trends
Serina Therapeutics has reported Return on Capital Employed for 7 years, with the latest figure at 392.58% in Q4 2025.
- Quarterly Return on Capital Employed fell 3090.0% year-over-year to 392.58% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 392.58% (down 3090.0% YoY) and the FY2025 annual result came in at 733.61%, down 42251.0% from the prior year.
- Return on Capital Employed rose to 392.58% in Q4 2025 per SER's latest filing, from 1237.5% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 2400.78% in Q1 2021 and troughed at 1237.5% in Q3 2025.
- A 5-year average of 58.16% and a median of 100.9% in 2022 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 575298 bps in 2021, down 260053 bps in 2021.
- Over 5 years, Return on Capital Employed stood at 128.44% in 2021, then slipped by 27 bps to 93.58% in 2022, then tumbled by 136 bps to 34.1% in 2023, then sank by 961 bps to 361.68% in 2024, then dropped by 9 bps to 392.58% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 392.58%, 1237.5%, and 521.26% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 7.88% |
| 10 | Serina Therapeutics | 43.44 Mn | 20.41 Mn | - | -197.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -197.68% |
| Dec 31, 2025 | -392.58% |
| Sep 30, 2025 | -1,237.50% |
| Jun 30, 2025 | -521.26% |
| Mar 31, 2025 | -470.46% |
| Dec 31, 2024 | -361.68% |
| Sep 30, 2024 | 253.42% |
| Jun 30, 2024 | 400.27% |
| Mar 31, 2024 | 108.22% |
| Dec 31, 2023 | -34.10% |
| Sep 30, 2023 | -163.58% |
| Jun 30, 2023 | 21.82% |
| Mar 31, 2023 | 28.49% |
| Dec 31, 2022 | 93.58% |
| Sep 30, 2022 | 108.36% |
| Jun 30, 2022 | 111.60% |
| Mar 31, 2022 | 108.85% |
| Dec 31, 2021 | 128.44% |
| Sep 30, 2021 | 204.01% |
| Jun 30, 2021 | 376.62% |